Custom Peptide Synthesis: What to Specify

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

A custom peptide order is a specification document, not a request. The things left unspecified are decided by whoever makes the material, according to their defaults, and those defaults are chosen for cost and throughput rather than for a particular experiment. This is a practical guide to what to state, and why each item is on the list.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The specification, item by item

Item	Why it has to be stated
Sequence with stereochemistry	D-residues are mass-silent; an unmarked D is a different compound with the same mass
N-terminal state	Free amine, acetylated, pyroglutamate — each is a distinct molecule
C-terminal state	Free acid or amide; changes charge, mass and protease susceptibility
Modifications and positions	Phosphorylation, biotinylation, fluorophores, PEG — position matters as much as presence
Disulfide pairing	With four or more cysteines, the correct pairing is one of several same-mass options
Purity and method	A percentage without a method cannot be interpreted
Counterion	Determines delivered mass and can affect cell systems
Quantity basis	Net peptide or gross weight — these differ by a double-digit percentage for some peptides
Analytical deliverables	Chromatogram and spectrum, or only summary figures

Which sequences are hard, and why that is your problem

The 2007 Nature Protocols paper by Coin and colleagues is the standard reference on solid-phase synthesis of difficult sequences, and it is worth reading before specifying anything unusual. The categories of difficulty are known:

Aggregation on the resin. Certain sequences form secondary structure during assembly, which blocks the growing chain from reacting. Yield collapses and deletion impurities accumulate.
Bulky and beta-branched residues. Valine, isoleucine and threonine couple more slowly; consecutive runs of them compound the problem.
Length. Stepwise yield is multiplicative. A small per-step inefficiency becomes a large overall one across forty residues, which is why long peptides are assembled in fragments and ligated.
Side-reaction-prone motifs. Asp-Gly and Asn-Gly sequences are prone to cyclisation and deamidation, producing impurities that are close in mass and may co-elute.
Multiple cysteines. Directed pairing requires orthogonal protecting-group strategies and sequential oxidation, which is a different and more expensive process than simple air oxidation.

Why does this matter to the person ordering? Because difficulty shows up as impurity profile, not as a failed order. A hard sequence delivered at the same headline purity as an easy one has a different population of impurities behind that number, and the impurities most likely to survive purification are the ones structurally closest to the target — single-residue deletions and isomers. Those are exactly the ones a purity figure does not resolve.

Where the method literature is going

Two recent papers illustrate that synthesis chemistry is still moving, which is relevant if a sequence has previously been quoted as infeasible. The 2019 paper by Merlino and colleagues in Organic Letters reports accelerating Fmoc synthesis by ultrasonication. The 2022 paper by Nandhini and colleagues in the Journal of Organic Chemistry describes a safety-catch linker for the Fmoc/tBu strategy — a linker that stays stable through assembly and is activated only for cleavage, which widens the range of conditions the peptide can be exposed to while on the resin.

Neither is a routine production method, but both are reasons to re-ask rather than assume a previous quotation still represents what is possible.

Purity: the specification people get wrong

The instinct is to specify the highest purity available. That is usually the wrong decision, and it is worth understanding why.

Purity above roughly 95 per cent is achieved by further preparative passes, each of which discards material. Cost rises and quantity falls. Meanwhile the headline percentage says nothing about which impurities remain. The 2008 study by Currier and colleagues documented impurities in commercial synthetic peptides and their consequences for immunological assessment — a demonstration that the identity of the contaminant, not the percentage, determines whether an experiment is compromised.

The better specification is therefore two-part: a purity figure appropriate to the work, plus a requirement for the chromatogram so the impurity profile can be inspected. The 2024 review by Kuril and colleagues in Analytical Biochemistry sets out what full characterisation of a peptide product involves from a regulatory standpoint, and it is a useful checklist even for research-grade material.

What the quotation will not include unless asked

Item	Request it when
Peptide content	Absolute concentration matters — which is most of the time
Counterion exchange to acetate	Working in cell culture
Water content	Weighing small quantities
Endotoxin testing	Any immune or inflammatory readout
Chromatogram and spectrum	Always, in practice
Chirality verification	The sequence contains D-residues by design

Peptide content is the one most often omitted and most often consequential. Purity describes how much of the peptide material is the right peptide; content describes what fraction of the vial weight is peptide at all. Our reconstitution calculator works from net mass, so entering gross vial weight produces a solution more dilute than intended — systematically, in one direction.

For catalogue material, the same reasoning applies in reverse: what you can verify is limited to what the certificate reports. Our BPC-157 research material ships with lot-specific data as a worked example of the minimum set.

Open questions

How much do impurity profiles differ between suppliers at the same stated purity?
Which sequence features best predict synthesis difficulty in practice?
How often does counterion identity measurably affect cell-based results?

Frequently asked questions

What has to be specified in a custom peptide order?

At minimum: the sequence in one-letter or three-letter code with stereochemistry, both terminal states, every modification with its position, the required purity and the method it is measured by, the counterion, the quantity as net peptide rather than gross weight, and the analytical data to be supplied.

Which sequences are difficult to synthesise?

Long sequences, those rich in beta-branched or bulky residues, those prone to aggregation on the resin, sequences containing multiple cysteines where specific pairing is needed, and those with Asp-Gly or Asn-Gly motifs that are prone to side reactions. The 2007 Nature Protocols paper on difficult sequences is the standard reference.

Does a higher purity specification always help?

Not necessarily, and it always costs more. Purity above about 95 percent is achieved by additional purification passes that reduce yield. What matters is whether the specific impurities present would interfere with the intended measurement, which is a different question from the headline percentage.

Why specify the counterion?

Because it is part of the delivered mass and it can affect experiments. Trifluoroacetate from purification is the default unless exchange is requested, and it is not inert in all biological systems. Acetate exchange is a separate specified step.

What is usually missing from a standard quotation?

Peptide content as distinct from purity, counterion identity and amount, water content, endotoxin, chromatograms rather than summary numbers, and chirality verification. Each has to be requested if it is needed.

References

Coin I, et al. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007. PMID: 18079725 https://pubmed.ncbi.nlm.nih.gov/18079725/
Merlino F, et al. Boosting Fmoc Solid-Phase Peptide Synthesis by Ultrasonication. Org Lett. 2019. PMID: 31361506 https://pubmed.ncbi.nlm.nih.gov/31361506/
Nandhini KP, et al. 2-Methoxy-4-methylsulfinylbenzyl Alcohol as a Safety-Catch Linker for the Fmoc/tBu Solid-Phase Peptide Synthesis Strategy. J Org Chem. 2022. PMID: 35801570 https://pubmed.ncbi.nlm.nih.gov/35801570/
Kuril AK, et al. Analytical considerations for characterization of generic peptide product: A regulatory insight. Anal Biochem. 2024. PMID: 39089363 https://pubmed.ncbi.nlm.nih.gov/39089363/
Currier JR, et al. Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment. Clin Vaccine Immunol. 2008. PMID: 18077621 https://pubmed.ncbi.nlm.nih.gov/18077621/